Precipio Inc.

Company Overview

Business Model: PRECIPIO, INC. is a healthcare biotechnology company dedicated to cancer diagnostics. Its core mission is to mitigate cancer misdiagnoses by developing and commercializing innovative diagnostic products and services. The company aims to deliver higher accuracy, improved laboratory workflow, better patient outcomes, and reduced healthcare expenses. PRECIPIO, INC. develops technologies within its CLIA-compliant laboratories in New Haven, Connecticut, and Omaha, Nebraska, where it also provides essential blood cancer diagnostics to oncologists nationwide. This integrated model allows the company to beta-test products in a clinical environment, significantly reducing development costs and accelerating time to market. As the "first user" of its own products, PRECIPIO, INC. optimizes laboratory functions and provides expert customer support. Products are commercialized through direct sales and partnerships with global healthcare distributors such as ThermoFisher, McKesson, Medline, and Cardinal Health.

Market Position: PRECIPIO, INC. operates within the United States domestic oncology market, addressing a significant problem of misdiagnosis in blood-related cancers, which can be as high as 28%. The company believes the diagnostic industry often prioritizes competitive pricing and turnaround times over quality and accuracy. The oncology total available market is estimated to exceed $20 billion, with a compound annual growth rate exceeding 5%. The diagnostics product market is projected to reach annual revenues exceeding $88 billion by 2025, also growing at an estimated 5% annually. PRECIPIO, INC.'s competitive advantage stems from its ability to identify real-world clinical challenges, develop technology-based solutions, validate them internally on clinical samples, and then commercialize these proven technologies.

Recent Strategic Developments:

• Product Launches & Enhancements: In 2024, PRECIPIO, INC. released BCR-ABL1 and Bloodhound MPN assays as part of its HemeScreen suite, offering lower limits of detection and quantitative results. These were accompanied by complementary analysis software (BHAS) to streamline laboratory workflows.
• Regulatory Milestones: HemeScreen reagents received CE-IVD marking in the EU on May 12, 2022, under the In Vitro Diagnostics Directive 98/79/EC. The company is actively transitioning to comply with the new In-Vitro Diagnostic Devices Regulation (EU) 2017/746.
• Financing Initiatives: On April 14, 2023, PRECIPIO, INC. entered into a sales agreement with A.G.P./Alliance Global Partners to sell up to $5.8 million of common stock. A prospectus supplement was filed on April 8, 2024, for the offer and sale of up to $1,061,478 of common stock. On May 1, 2024, the company secured a $250,000 business loan from Altbanq Lending LLC.
• Corporate Governance: On August 30, 2024, the Board of Directors approved a one-time stock option repricing for certain options with exercise prices exceeding $6.56.

Geographic Footprint: PRECIPIO, INC. primarily operates in the United States, with laboratory and research and development facilities located in New Haven, Connecticut, and Omaha, Nebraska. It provides diagnostic blood cancer testing services to oncology practices in over 20 states. The company anticipates international marketing following successful U.S. deployment, with its products regulated as in-vitro diagnostic devices in the European Union and the UK.

Financial Performance

Revenue Analysis

Profitability Metrics:

• Gross Margin: 41% (2024) vs. 40% (2023)
• Operating Margin: -22.8% (2024) vs. -50.1% (2023)
• Net Margin: -23.2% (2024) vs. -38.5% (2023)

Investment in Growth:

• R&D Expenditure: $1.3 million (7.0% of revenue) in 2024, compared to $1.7 million (11.2% of revenue) in 2023.
• Capital Expenditures: $0.2 million in 2024, compared to $0.1 million in 2023.
• Strategic Investments: Not explicitly detailed as separate line items beyond R&D and capital expenditures.

Business Segment Analysis

PRECIPIO, INC. operates as a single operating segment, with its Chief Executive Officer serving as the chief operating decision maker. The company's revenue is disaggregated by transaction type and payer class.

Revenue Breakdown by Type (Net Sales):

• Service Revenue, Net: $15.9 million in 2024, an increase of 31% from $12.2 million in 2023. This growth was primarily driven by a 76% increase in cases processed (11,894 cases in 2024 vs. 6,765 cases in 2023), partially offset by a lower average price per case due to a different product mix.
• Product Revenue: $2.6 million in 2024, a decrease of 14% from $3.0 million in 2023.

Revenue Breakdown by Payer (Service Revenue, Net, in millions):

• Medicaid: $0.04 (2024) vs. $0.03 (2023)
• Medicare: $6.36 (2024) vs. $5.00 (2023)
• Self-pay: $0.04 (2024) vs. $0.16 (2023)
• Third party payers: $9.48 (2024) vs. $7.21 (2023)
• Contract diagnostics and other: $0.05 (2024) vs. $0.01 (2023)

Key Growth Drivers:

• Significant increase in diagnostic service case volume (76% year-over-year).
• Ongoing development and commercialization of proprietary diagnostic products like HemeScreen and IV-Cell.
• Strategic partnerships with global healthcare distributors for market access.

Product Portfolio:

• HemeScreen: A suite of disease-specific reagents utilizing inexpensive RT-PCR technology for genetic testing in blood cancers. It offers targeted panels (typically 4-7 genes) that align with clinical requirements, can be run on a single, low-cost platform, require basic laboratory training, and provide attractive economics to laboratories. Recent additions in 2024 include BCR-ABL1 and Bloodhound MPN assays with lower limits of detection and quantitative results, along with complementary analysis software (BHAS).
• IV-Cell: A proprietary universal cell culture media designed to address diagnostic errors in cytogenetics by enabling simultaneous culturing of all four hematopoietic cell lineages (myeloid, B-cell, T-cell, and Plasma). This technology has demonstrated superior results compared to existing commercial reagents like MarrowMax and has been used on over 1,000 clinical specimens in PRECIPIO, INC.'s laboratory.

Capital Allocation Strategy

Shareholder Returns:

• Share Repurchases: PRECIPIO, INC. made no share repurchases during the year ended December 31, 2024.
• Dividend Payments: No cash dividends have been paid on common stock, and the company does not expect to pay dividends in the foreseeable future, with any income devoted to future operations and growth.
• Future Capital Return Commitments: No authorized programs or amounts for future capital returns were disclosed.

Balance Sheet Position (as of December 31, 2024):

• Cash and Equivalents: $1.4 million
• Total Debt: $0.37 million (comprising $0.30 million in current maturities and $0.08 million in long-term debt, net of current maturities).
• Net Cash Position: $1.01 million.
• Credit Rating: Not disclosed.
• Debt Maturity Profile (Principal amounts in thousands):
  • 2025: $300
  • 2026: $33
  • 2027: $34
  • 2028: $16
  • Total: $383
• PRECIPIO, INC. reported a working capital deficit of $0.8 million as of December 31, 2024, and an accumulated deficit of $102.4 million. The independent registered public accounting firm has issued an opinion raising substantial doubt about the company's ability to continue as a going concern.

Cash Flow Generation (Year Ended December 31, 2024):

• Operating Cash Flow: $0.4 million (provided). This marks a significant improvement from -$3.6 million used in 2023.
• Free Cash Flow: $0.2 million (calculated as operating cash flow less capital expenditures).
• Cash Conversion Metrics: Not explicitly detailed, but the positive operating cash flow in 2024 indicates improved cash generation from core business activities.

Operational Excellence

Production & Service Model: PRECIPIO, INC. operates CLIA and CAP certified clinical pathology and molecular laboratories in New Haven, Connecticut, and Omaha, Nebraska. These facilities are central to both its diagnostic service offerings and its R&D efforts. The company's strategy involves utilizing its clinical labs for beta-testing new products on real clinical samples, which significantly reduces development costs and timelines. This "first-user" approach also allows PRECIPIO, INC. to optimize laboratory functions such as workflow, inventory management, regulatory compliance, and billing, enabling it to provide high-level, hands-on, expert support to its customers.

Supply Chain Architecture: Key Suppliers & Partners:

• Global Healthcare Distributors: ThermoFisher, McKesson, Medline, and Cardinal Health are key partners forming the backbone of the company's go-to-market strategy for diagnostic products.
• Manufacturing Partner (IV-Cell): PRECIPIO, INC. contracts with a manufacturer, under license and non-disclosure, to produce its proprietary IV-Cell media.
• Reagent Suppliers: The company has entered into purchase commitments for reagents from various suppliers, with agreements running through 2031.
• Billing Services: PRECIPIO, INC. utilizes Change Healthcare for processing pathology service billings. A cybersecurity breach at Change Healthcare in February 2024 caused temporary disruptions, billing delays, and incurred approximately $0.3 million in expenses for PRECIPIO, INC. The company received $1.1 million through Change Healthcare's Temporary Funding Assistance Program in 2024 and is negotiating a repayment plan.

Facility Network:

• Manufacturing: While not explicitly stated as separate manufacturing facilities, product development and testing occur within its laboratories.
• Research & Development: Dedicated R&D facilities are co-located with laboratories in New Haven, Connecticut, and Omaha, Nebraska.
• Distribution: Leverages its network of global healthcare distributors for product distribution.
• Laboratory & Office Space:
  • New Haven, Connecticut: Leases approximately 11,382 square feet of laboratory and office space under a lease expiring in February 2030.
  • Omaha, Nebraska: Leases approximately 5,300 square feet of laboratory space under a lease expiring in May 2025, with renewal options currently under evaluation.

Operational Metrics:

• Cases Processed: 11,894 cases processed in 2024, a 76% increase compared to 6,765 cases in 2023.
• Turnaround Time Improvement: Customers utilizing HemeScreen have demonstrated a reduction in test turnaround time from 2 weeks to 2 days.

Market Access & Customer Relationships

Go-to-Market Strategy: Distribution Channels:

• Direct Sales: PRECIPIO, INC.'s Products Division commercial team is responsible for generating direct sales.
• Channel Partners: The company collaborates with global healthcare distributors, including ThermoFisher, McKesson, Medline, and Cardinal Health, to access laboratories across the country.
• Digital Platforms: Laboratory reports are delivered to customers via web-portal access or fax.

Customer Portfolio: Enterprise Customers:

• PRECIPIO, INC. provides diagnostic blood cancer testing services to oncology practices in over 20 states across the U.S.
• Customer Concentration: In 2024, one customer accounted for 17% of total revenue and 29% of total accounts receivable. In 2023, one customer represented 11% of total revenue and 13% of total accounts receivable. The company expects to maintain ongoing relationships with its customers.

Geographic Revenue Distribution:

• Primary Market: The United States domestic oncology market is the company's primary focus.
• International Expansion: PRECIPIO, INC. anticipates international marketing following successful deployment within the United States.
• European Union: HemeScreen reagents received CE-IVD marking in the EU in May 2022, under the previous IVDD. The company is actively working towards re-certification under the new IVDR.

Competitive Intelligence

Market Structure & Dynamics

Industry Characteristics: The medical diagnostic industry, particularly in cancer diagnostics, is intensely competitive and characterized by rapid technological progress. PRECIPIO, INC. operates in a market where misdiagnosis rates for blood-related cancers can be as high as 28%, driven by an industry focus on competitive pricing and test turnaround times at the expense of quality and accuracy. Despite discussions of a shift from fee-per-service to value-based payments, this transition has not yet materialized in diagnostics. The oncology total available market is estimated to exceed $20 billion, with a compound annual growth rate exceeding 5%, while the diagnostics product market is projected to reach over $88 billion by 2025, also growing at 5% annually.

Competitive Positioning Matrix:

Direct Competitors

Primary Competitors (Clinical Pathology Services):

• Specialized Oncology Services: NeoGenomics Laboratories, Inc., GenPath Diagnostics, Inform Diagnostics.
• Large Commercial Laboratories: LabCorp, Quest Diagnostics.
• Liquid Biopsy Market: Foundation Medicine, Guardant Health.

Primary Competitors (Products Division - Reagent Manufacturers):

• Single-gene testing assays: Qiagen, BioRad, Ipsogen, Cepheid, Asuragen, Abbott, Entrogen.
• Next Generation Sequencing (NGS) panels: Life Technologies, Illumina, Roche, Natera, PerkinElmer, BioRad, Qiagen.
• Cell culture media: Gibco, Irvine Scientific, Capricorn Scientific, Sigma-Aldrich, Euroclone.

Emerging Competitive Threats: The industry faces continuous threats from new entrants, disruptive technologies, and alternative solutions. Many competitors possess significantly greater financial resources and expertise in research and development, manufacturing, clinical trials, regulatory approvals, and marketing.

Competitive Response Strategy: PRECIPIO, INC.'s strategy involves developing, manufacturing, and selling multiple proprietary technologies that are more cost-effective and improve efficiencies. By embedding R&D within its clinical laboratory operations, the company ensures product relevance, reliability, and workability within the laboratory workflow. This model also provides unique insights for customer support and focuses on improving laboratory economics, complex results delivery, and proprietary analysis to minimize misdiagnoses.

Risk Assessment Framework

Strategic & Market Risks

Market Dynamics:

• Market Acceptance: Commercial success is contingent on widespread market acceptance of products by physicians, patients, healthcare payers, and the medical community.
• Competition: Intense competition from companies with significantly greater financial and R&D resources, potentially leading to new diagnostic tools or more effective/less expensive alternatives.
• Technological Obsolescence: Rapid technological change and innovation in the medical diagnostic industry pose a risk that new technologies could emerge, offering superior price and performance.
• Economic Conditions: Unfavorable U.S. or global economic conditions, including inflation, rising interest rates, and trade disputes, could adversely affect demand, capital raising, and supply chain stability.
• Geopolitical Events: Global conflicts (e.g., Russia-Ukraine, Israel-Hamas), acts of terror, political unrest, public health concerns, labor disputes, or natural disasters could disrupt operations, supply chains, and customer/supplier activities.
• U.S. Policy Changes: Substantial changes to U.S. federal fiscal, tax, trade, and regulatory policies could adversely impact business operations and financial results.

Operational & Execution Risks

Supply Chain Vulnerabilities:

• Supplier Dependency: Reliance on a limited number of key suppliers for reagents and other materials.
• Billing Service Disruption: The 2024 cybersecurity breach at Change Healthcare, a key billing processor, caused significant delays in billing and cash reimbursements, and incurred additional expenses.
• Facility Concentration: All diagnostic technology development and clinical services are performed at two laboratories (New Haven, Connecticut, and Omaha, Nebraska). Termination of leases or man-made/natural disasters at these facilities could severely impair operations.
• Labor Availability: Dependence on a limited number of key personnel and the ability to attract and retain highly qualified scientific, commercial, and administrative staff.

Financial & Regulatory Risks

Market & Financial Risks:

• Going Concern Doubt: Substantial doubt exists about PRECIPIO, INC.'s ability to continue as a going concern due to recurring operating losses, negative cash flow in prior years, and a working capital deficit.
• Capital Requirements: Significant additional financing may be required to sustain operations and commercialize diagnostic technology, with no assurance of availability on acceptable terms.
• Profitability: History of incurring losses since inception, with no certainty of achieving or sustaining profitability.
• Revenue Concentration: Dependence on a few large customers, with one customer accounting for 17% of total revenue and 29% of accounts receivable in 2024, posing concentration risk.
• Product Liability: Inherent risk of product liability and personal injury claims, which could exceed insurance coverage.
• Intangible Asset Impairment: Risk of impairment in the carrying value of intangible assets if business plans are not realized.
• Tax Law Changes: Changes in U.S. federal, state, and local tax laws could adversely affect financial condition.
• NOL Limitations: The ability to utilize approximately $79 million in federal net operating loss carryforwards and $2.5 million in state NOLs may be significantly limited by Section 382 ownership changes or other regulatory changes.

Regulatory & Compliance Risks:

• Extensive Healthcare Regulation: Subject to complex and rapidly changing federal, state, and local laws governing licensure, accreditation, reimbursement, and fraud and abuse (e.g., Anti-Kickback Statute, Stark Law, False Claims Act).
• Reimbursement Policies: Governmental payers (Medicare, Medicaid) and private insurers implement cost control measures, which could negatively affect coverage and reimbursement rates for services.
• CLIA Certification: Ongoing CLIA certification is required for laboratories; failure to pass inspections could lead to severe penalties, including suspension or revocation of certificates.
• FDA Regulation of RUO/LDTs: Products labeled "Research Use Only" (RUO) or offered as Laboratory Developed Tests (LDTs) could become subject to extensive FDA medical device regulations, requiring costly and time-consuming marketing authorization processes. The FDA's final rule on LDTs (April 29, 2024) and ongoing lawsuits challenging its authority create significant regulatory uncertainty.
• EU/UK Regulation: Products are regulated as in-vitro diagnostic devices in the EU (IVDR) and UK (UKCA), requiring CE marking and compliance with evolving, stringent requirements, which may lead to delays and increased costs.
• Privacy Laws: Subject to stringent and changing U.S. federal/state (e.g., HIPAA, CCPA, CPRA, My Health My Data Act) and foreign (e.g., GDPR) data protection laws, imposing significant compliance costs and risks of enforcement actions or litigation.
• Artificial Intelligence: The use of AI in business processes may introduce cybersecurity risks, reputational harm, and legal liability if not managed responsibly and in compliance with evolving standards.

Innovation & Technology Leadership

Research & Development Focus: PRECIPIO, INC.'s R&D efforts are strategically focused on addressing the root causes of cancer misdiagnoses, particularly in the hematologic field. Core Technology Areas:

• Cancer Diagnostics: Developing solutions for higher accuracy and improved diagnostic outcomes in various diseases within the hematologic field.
• Genetic Diagnostics: Expertise in creating robust genetic diagnostic panels, exemplified by the HemeScreen technology.
• Laboratory Workflow Optimization: Innovating to improve laboratory efficiency, reduce technician time, and accelerate test turnaround times.
• Cost-Effective Solutions: Prioritizing the development of technologies that are more economically practical for clinical use than current industry alternatives.
• Innovation Pipeline: The company maintains a robust pipeline of products under development, with expectations for future launches. Its R&D team is integrated into clinical laboratory operations, enabling efficient identification of challenges and creation of proprietary product solutions.

Intellectual Property Portfolio:

• Patent Strategy: PRECIPIO, INC. owns pending U.S. and European patent applications for its proprietary HemeScreen technology, aiming to reinforce its commitment to innovation and strengthen its market position.
• Trademark Strategy: The company has registered trademarks to safeguard its brand identity and ensure the distinctiveness of its products in the marketplace.
• Trade Secrets: Relies on trade secret protection, know-how, and continuous technological innovation, secured through confidentiality and invention assignment agreements with employees, contractors, and collaborators.

Technology Partnerships:

• Strategic Alliances: PRECIPIO, INC. has an Amended and Restated Pathology Services Agreement with Yale University, dated March 21, 2017.
• Manufacturing Collaborations: The company has a direct supply contract with a manufacturer, under license and non-disclosure, to produce its IV-Cell media.

Leadership & Governance

Executive Leadership Team

| Position | Executive | Tenure